Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company focused on intelligent, rapid, non-invasive testing solutions, with a primary emphasis on its Intelligent Fingerprinting Drug Screening System. The INBS news feed on Stock Titan aggregates company announcements, press releases and related coverage so readers can follow developments around its fingerprint-based drug screening platform, partnerships and capital markets activity.
Recent news highlights include record fiscal 2026 first quarter revenue driven by consumable cartridge sales, the addition of dozens of new customer accounts across more than 24 countries, and large deployments with organizations in sectors such as industrial services and public transport. Updates also cover the company’s razor–razor-blade business model, where installed readers support recurring cartridge revenue, and its efforts to expand adoption in safety-critical industries like construction, manufacturing and engineering, transport and logistics, mining and government administration.
INBS news items frequently address strategic partnerships and manufacturing, such as the collaboration with Syrma Johari MedTech Ltd to scale production of the Intelligent Fingerprinting Drug Screening Reader, and the alliance with Vlepis Pty Ltd to explore wearable patch technologies and consumer health monitoring. Additional coverage includes the distribution agreement for the SmarTest Patch, a 7–10 day continuous drug monitoring solution, and updates on regulatory pathways, including anticipated FDA 510(k) submissions.
Investors can also track capital structure and listing-related developments, including reverse stock split decisions, Nasdaq bid price deficiency notices and private placement financings with institutional investors. By reviewing the INBS news stream, readers gain context on how Intelligent Bio Solutions is executing its commercial strategy, expanding its customer base, managing manufacturing partnerships and addressing regulatory and listing requirements over time. Bookmark this page to quickly access the latest official communications and market-moving updates related to INBS.
Intelligent Bio Solutions (Nasdaq: INBS) has provided an updated timeline for FDA 510(k) clearance of its Intelligent Fingerprinting Drug Screening System for opiate codeine detection. Following FDA feedback, the company will conduct additional clinical studies starting before year-end 2025, with completion expected in H1 2026. FDA clearance is anticipated in H2 2026.
The company's drug testing technology has already gained significant traction globally, with 450 accounts across 24 countries and 18 distribution partners. INBS continues to expand its presence in various industries including construction, transportation, logistics, and mining, while working to move beyond the Forensic Use Only market in the US.
Intelligent Bio Solutions (Nasdaq: INBS) provided an update on the FDA 510(k) clearance process for its Intelligent Fingerprinting Drug Screening System. Following their December 2024 submission, the FDA issued an Additional Information request in February 2025 with over 70 items to address.
After responding in August 2025, the FDA has requested new additional information requiring a new 510(k) notification submission. Being a first-of-its-kind sweat-based device, the extensive requirements are not uncommon for breakthrough technologies. The company expects to provide an investor update on the revised FDA clearance timeline within 10 days.
Meanwhile, INBS continues to expand its international business operations outside the U.S. market.
Intelligent Bio Solutions (Nasdaq: INBS) reported record-breaking monthly cartridge sales in July 2025, shipping 519 boxes containing over 12,500 cartridges, marking a 60% year-over-year increase. The company's fingerprint sweat-based drug testing system operates on a razor/razor blade business model, where cartridges serve as high-margin consumables.
INBS secured a significant multi-site contract in the transportation sector and is experiencing growing demand for its drug testing solutions. The company plans to expand beyond Forensic Use Only settings in the U.S. market during the second half of 2025, while focusing on leveraging its installed base to drive recurring cartridge sales.
Intelligent Bio Solutions (Nasdaq: INBS) reported its fiscal Q4 and full-year 2025 results, highlighting significant progress in its U.S. market expansion plans and operational performance. The company achieved 16% revenue growth both sequentially and year-over-year in Q4, reaching $843,884, driven by increased drug testing cartridge demand.
Key developments include advancement toward FDA 510(k) clearance for its opiate test system, expansion of its international presence to over 450 accounts across 24 countries, and a 24% year-over-year increase in cartridge sales for Q4. The company implemented operational efficiencies, launched multilingual support, and strengthened its intellectual property with a sixth U.S. patent.
Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on rapid, non-invasive testing solutions, has announced its participation in the upcoming Sidoti Micro-Cap Virtual Conference. The company's management team will present on Thursday, August 21, 2025, at 9:15 a.m. Eastern Time.
Investors can access the presentation through a webcast link and schedule one-on-one meetings with management through Sidoti representatives or KCSA Strategic Communications.
Intelligent Bio Solutions (Nasdaq: INBS) announced preliminary fiscal Q4 2025 results, highlighting 16% revenue growth both sequentially and year-over-year. The growth was driven by increased higher-margin cartridge sales and steady account expansion.
The company made significant operational progress, including submitting an FDA 510(k) application for its opiate test system for codeine. INBS also completed multilingual upgrades to its Intelligent Fingerprinting Drug Screening System and launched localized websites with enhanced CRM workflows across Europe, the Middle East, and Latin America.
Final audited results will be disclosed in the Annual Report on Form 10-K, expected during the week of August 11, 2025.
Intelligent Bio Solutions (Nasdaq: INBS) has submitted additional information to the FDA as part of its 510(k) clearance process for its fingerprint sweat-based drug screening technology. The submission includes extensive new cybersecurity and performance data, comprising 23 test reports and over 100 supporting attachments totaling more than 1900 pages.
The company invested 10,000 hours in data collection and conducted intensive cybersecurity testing, including penetration and electromagnetic compatibility testing. The technology's accuracy was reaffirmed using advanced quantification methods, including human eccrine sweat testing with an Ultra-Micro Balance scale.
Currently used across 450 accounts in 24 countries, INBS expects an FDA response within six weeks and aims to enter the multi-billion-dollar U.S. market in 2025, focusing initially on its opiate test system for codeine.
Intelligent Bio Solutions (Nasdaq: INBS) has secured a significant contract with a major London transport operator to implement its Intelligent Fingerprinting Drug Screening System across 14 operational sites serving over 4,400 staff. The transport operator manages a fleet of 1,400+ low-emission vehicles and serves more than one million passengers daily.
The company's drug testing technology is currently utilized by 450+ accounts across 24 countries through 18 distribution partners. INBS is actively expanding globally and pursuing FDA clearance for planned entry into the U.S. market in 2025.
Intelligent Bio Solutions (Nasdaq: INBS) has secured agreements to raise $3.8 million in gross proceeds through warrant exercises at a reduced price of $1.90 per share. The transaction involves current warrant holders exercising or prepaying existing warrants for 2,023,228 shares of common stock.
As part of the deal, participating holders will receive new Inducement Warrants for up to 4,046,456 shares at $1.90 per share, exercisable for 5.5 years after stockholder approval. The company plans to use the proceeds to complete its 510k filing with the FDA for its Fingerprint Drug Screening System and for working capital purposes. The transaction is expected to close around July 28, 2025.
Intelligent Bio Solutions (Nasdaq: INBS) announced new data strengthening its FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System. The company completed extensive cybersecurity and electromagnetic compatibility testing to validate system resilience. Using an Ultra-Micro Balance scale capable of measuring 0.0000001 grams, INBS confirmed its technology's ability to detect and analyze trace levels of fingerprint sweat.
The R&D team has invested over 6,000 hours into testing, data aggregation, analysis, and technical reporting. INBS currently supports more than 450 accounts across 24 countries with 18 distribution partners. The company plans to enter the U.S. market in 2025, pursuing FDA clearance for its opiate test system for codeine.
FAQ
What is the current stock price of Intelligent Bio Solutions (INBS)?
What is the market cap of Intelligent Bio Solutions (INBS)?
